24 September 2025
24 September 2025
Tylenol’s label change plus the approval of Wellcovorin offer a taste of the Trump administration’s plans to crack down on the US “autism epidemic”.
The API facility is part of Eli Lilly’s $27bn US manufacturing drive.
Eli Lilly and Novo Nordisk are in a tight race to capture the lucrative oral obesity drug market – but how will their competing treatments reshape the landscape?
Alirocumab was found to have reduced cardiovascular events by 49.5% in patients with diabetes and by 42.3% in those without.
This is the second therapy available, expanding options beyond surgery and the limited use of interferon marketed in Russia.
Bucking the trend of IL-12 therapy program failures, Imunon’s IMNN-001 was bolstered by positive translational data in ovarian cancer.
While only two therapies have so far gained approval, there is strong research and development activity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
